Peptide Dose Timing: What Is and Isn't Known

What this page covers

Most timing advice for peptides concerns growth hormone (GH) secretagogues: compounds such as ipamorelin and CJC-1295 that prompt the pituitary to release its own GH. Forum guides tell readers to dose before bed or near training, usually on an empty stomach. Those rules borrow from real physiology: GH release follows sleep, and food suppresses it. The rules themselves have almost never been tested with the peptides people use.

This page keeps the two apart. Physiology comes first. After that come user and vendor practice, and the places where the two disagree.

The natural nighttime pulse

In a 1968 study, researchers drew blood every 30 minutes through the night from eight young adults. In seven of them, a large GH peak lasting 1.5-3.5 hours appeared at the onset of deep sleep. When sleep was delayed, the peak was delayed too. People woken for 2-3 hours and then allowed back to sleep produced a second peak. The surge didn't track blood glucose or insulin, which pointed to the brain's sleep machinery as the trigger.

Later work tied the pulse to slow-wave (deep) sleep specifically. A 2000 review by Van Cauter and Copinschi describes a roughly linear relationship between the amount of slow-wave sleep and the GH released alongside it. The pattern differs by sex. In healthy men the sleep-onset pulse is often the main or only burst of the day, while women also have frequent daytime pulses.

A JAMA analysis the same year pooled data on 149 healthy men from four laboratories. Deep sleep fell from about 19% of the night at ages 16-25 to about 3% at ages 36-50. GH secretion fell in parallel, by about 372 mcg per decade over that span, and the link between slow-wave sleep and GH held regardless of age.

That decline is the main argument behind bedtime dosing. If most of a middle-aged man's GH comes in one early-night burst, a secretagogue given shortly before sleep could in theory add to it. As of October 2026, we found no published trial testing whether that produces better outcomes than dosing at another time. Our page on timing doses around sleep covers the night-time question in more detail.

Food, insulin and fatty acids

Nutrition moves GH release in both directions. A 1963 paper in Science showed that low blood sugar is a strong GH stimulus in healthy people. In a 1988 study of six men, a five-day fast also raised the number of GH pulses from about 6 to about 10 per day, and total 24-hour GH roughly tripled.

Raised glucose and fat do the opposite, and the size of the effect depends on the peptide class. In a 1995 study of six healthy men, a 100 g glucose drink cut the peak GH response to GHRH (the hormone CJC-1295 mimics) from about 20 to about 6 mcg/L. The same glucose load only blunted the response to hexarelin, a ghrelin-receptor agonist, from about 63 to 38 mcg/L. An IV fat infusion produced almost the same split, and a 2002 study found a similar pattern with ghrelin itself.

Insulin adds its own brake. In a 1999 study, an insulin infusion that reproduced after-meal insulin levels cut the GH response to GHRH in both lean and obese volunteers, compared with a drug that lowered fatty acids without raising insulin. The GH response fell as insulin rose.

These studies used glucose drinks or IV fat rather than ordinary meals, and they gave the peptides intravenously. They support the idea that eating shortly before a dose can shrink the GH it produces, especially for GHRH analogs. They don't establish a specific fasting window. Our page on how meals interact with GH peptides goes further into the food question.

Training and the exercise pulse

Exercise releases GH as well. A 2005 review of resistance training found that GH rises during a demanding session and stays up for 15-30 minutes afterward. A 2002 review covering both aerobic and resistance exercise found that the size of the GH rise grows with intensity and is 4-7 times smaller in older adults.

Whether that short rise matters for muscle is less clear. In a 2010 McMaster University study, 12 young men trained each arm separately for 15 weeks. One arm's workouts were followed by heavy leg exercise that raised circulating hormones, GH included. The other arm trained with hormones at baseline. Muscle size grew by 12% and 10%, with no real difference between arms, and strength rose equally.

That weakens the common case for timing a peptide to the exercise pulse. The specific practices users describe are covered on our pages on pre-workout peptide timing and post-workout peptide timing.

How peptides fit the clock

Timing matters most for short-acting compounds. In a 1999 study of healthy men, an IV ipamorelin infusion produced a single GH burst that peaked about 40 minutes in and then faded; the drug's half-life was about 2 hours. The DAC form of CJC-1295 behaves very differently. In 2006 trials in healthy adults, its half-life was 5.8-8.1 days, and one injection kept GH raised for 6 days or more, so the hour of injection matters far less.

Prescription labels say less than forum guides do. Egrifta WR (tesamorelin) is a prescription GHRH analog approved for excess abdominal fat in adults with HIV-associated lipodystrophy. Its FDA label lists 1.28 mg once daily by subcutaneous injection into the abdomen. The dosing section gives no time of day and no fasting rule.

Bedtime doses also affect sleep itself, and not always in the same direction. In a 1997 crossover trial, MK-677 at 25 mg taken at bedtime for a week raised stage 4 sleep by about 50% in eight young adults. A 1995 study of GHRP-6, given as four repeated 50 mcg IV injections, increased light stage 2 sleep but left slow-wave sleep unchanged, while raising cortisol. In 2004 the same Munich group gave hexarelin on that 4 x 50 mcg schedule, hourly from 10 p.m. to 1 a.m., and found less deep sleep in the first half of the night in seven volunteers. These are small studies, mostly with IV dosing, but they show the compound matters.

What users report

Among users, bedtime is the most common slot for short-acting GH peptides. Forum posts typically describe a dose 30-60 minutes before sleep, two to three hours after the last meal. Many add a second fasted dose on waking and hold off eating for 30-60 minutes afterward. Some people say they sleep more deeply on this schedule. Others move their dose to the morning because a bedtime injection leaves them restless.

One vendor guide published in August 2026 calls night-time fasted dosing "the default" for CJC-1295 without DAC plus ipamorelin. It lists a multi-dose pattern of 100 mcg of each taken two or three times a day, every dose fasted. The same guide acknowledges that no published trial compares morning and night dosing for this pairing.

Where evidence and practice meet

Some user habits fit the physiology well. Avoiding food before a GHRH analog dose matches the 1995 and 1999 studies, and choosing bedtime matches the sleep-onset pulse. Other habits go beyond the data. The exact two-hour or three-hour fasting window has no study behind it. The idea that a peptide "amplifies" the natural pulse assumes the two effects add together, which nobody has measured with these peptides during sleep. The hexarelin study even shows that a bedtime dose can reduce the deep sleep the strategy relies on.

There's also a gap between hormone levels and results. Apart from the 2010 training study, the studies above measured GH in the blood rather than body composition or recovery. User reports of better sleep are worth recording, but they come from people who picked a schedule and expected it to help, so expectation effects are hard to rule out.

What we still don't know

• As of October 2026, we found no trial comparing bedtime with morning dosing for any outcome, for any GH peptide sold for research use.
• Nobody has measured how an ordinary mixed meal, rather than a glucose drink, changes the response to a subcutaneous dose.
• It's unknown whether ipamorelin or Mod GRF 1-29 changes sleep structure the way hexarelin and MK-677 did.
• No study has asked whether women's more frequent daytime GH pulses should change timing for them.